We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock

Delisted

VYNT was delisted on the 12th of May, 2023.

28 hedge funds and large institutions have $12.6M invested in Vyant Bio, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

22% more capital invested

Capital invested by funds: $10.4M → $12.6M (+$2.25M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less funds holding

Funds holding: 3228 (-4)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
28
Holders Change
-4
Holders Change %
-12.5%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
10
Reduced
8
Closed
9
Calls
$419K
Puts
Net Calls
+$419K
Net Calls Change
+$419K

VYNT Hedge Fund Activity: Q2 2017 in Review

28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2017, worth a combined $12.6M — up 22% from $10.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of VYNT and 5 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 10 added.

The largest buyer was UBS Group, adding an estimated $799K. The largest seller was Panagora Asset Management, cutting an estimated $139K.

  • 28 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2017, down from 32 in Q1 2017.
  • Funds reported $12.6M of Vyant Bio, Inc. Common Stock stock for Q2 2017, up 22% quarter-over-quarter.
  • 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2017 and 9 closed out, a net change of -4 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q2 2017 was UBS Group, an estimated $799K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q2 2017 was Panagora Asset Management, an estimated $139K sold.

Based on aggregated 13F filings for Q2 2017.